LGM
DYN icon

Logos Global Management’s Dyne Therapeutics DYN Stock Holding History

Logos Global Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.6M Buy
2,550,000
+1,150,000
+82% +$21.4M 2.44% 14
2026
Q1 		$25.4M Buy
1,400,000
+150,000
+12% +$2.59M 1.27% 28
2025
Q4 		$24.4M Sell
1,250,000
-1,150,000
-48% -$21.8M 1.48% 24
2025
Q3 		$30.4M Buy
2,400,000
+500,000
+26% +$5.7M 2.72% 14
2025
Q2 		$18.1M Buy
1,900,000
+1,400,000
+280% +$15.4M 2% 17
2025
Q1 		$5.23M Buy
500,000
+50,000
+11% +$715K 0.93% 25
2024
Q4 		$10.6M Buy
450,000
+290,000
+181% +$8.58M 1.24% 29
2024
Q3 		$5.75M Sell
160,000
-105,000
-40% -$4.18M 0.62% 37
2024
Q2 		$9.35M Sell
265,000
-1,465,000
-85% -$42.6M 0.75% 35
2024
Q1 		$49.1M Sell
1,730,000
-150,000
-8% -$3.39M 3.98% 9
2023
Q4 		$25M Sell
1,880,000
-300,000
-14% -$2.93M 2.33% 15
2023
Q3 		$19.5M Buy
2,180,000
+400,000
+22% +$4.31M 2.61% 13
2023
Q2 		$20M Buy
1,780,000
+80,000
+5% +$944K 2.72% 14
2023
Q1 		$19.6M Sell
1,700,000
-450,000
-21% -$5.84M 2.8% 13
2022
Q4 		$24.9M Sell
2,150,000
-137,321
-6% -$1.59M 2.92% 15
2022
Q3 		$29M Sell
2,287,321
-612,679
-21% -$7.02M 3.57% 11
2022
Q2 		$19.9M Buy
2,900,000
+165,608
+6% +$1.14M 3.66% 12
2022
Q1 		$26.4M Sell
2,734,392
-500,000
-15% -$4.26M 3.42% 16
2021
Q4 		$38.5M Sell
3,234,392
-385,000
-11% -$5.41M 3.97% 8
2021
Q3 		$58.8M Buy
3,619,392
+1,565,000
+76% +$27.7M 4.24% 5
2021
Q2 		$43.2M Sell
2,054,392
-1,150,000
-36% -$21.6M 3.63% 5
2021
Q1 		$49.8M Buy
3,204,392
+1,600,000
+100% +$31M 4.86% 4
2020
Q4 		$33.7M Hold
1,604,392
– – 2.89% 6
2020
Q3 		$32.4M Buy
+1,604,392
New +$35.2M 4.15% 8

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Logos Global Management's DYN Position: Q2 2026 in Review

Logos Global Management increased its Dyne Therapeutics (DYN) stake by 82% in Q2 2026, buying an estimated $21.4M and bringing the position to 2,550,000 shares worth $56.6M. The position accounts for 2.44% of the portfolio, ranked #14.

Logos Global Management first reported a position in DYN in Q3 2020 and has held it in 24 quarters since. The position peaked at $58.8M in Q3 2021. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Logos Global Management held 2,550,000 shares of Dyne Therapeutics worth $56.6M as of Q2 2026.
  • Logos Global Management bought 1,150,000 Dyne Therapeutics shares in Q2 2026, an estimated $21.4M.
  • Dyne Therapeutics made up 2.44% of Logos Global Management's portfolio in Q2 2026, its #14 holding.
  • Logos Global Management first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Logos Global Management's Dyne Therapeutics position peaked at $58.8M in Q3 2021.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.